Compare Novartis AG (NVS) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Quantumscape Corp — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Quantumscape Corp trades at $4.67 (market cap $2.78B). The key difference: Novartis AG is far larger — about 98.6× Quantumscape Corp's market cap, and Novartis AG pays a 3.31% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Quantumscape Corp for 37 Days on average.
| NVS | QS | |
|---|---|---|
Market Cap | $274.00B | $2.78B |
Volume | 1,852,137 | 11,236,221 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $18.44 |
52-Week Low | $121.80 | $4.52 |
Typical Hold Time | 82 Days | 37 Days |
Enterprise Value | $315.32B | $1.99B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
QuantumScape (QS) trades at $4.58, down 1.51% on the day, with a bearish technical outlook and no current revenue generation. The company reported a net loss of $435.05 million in 2025 and faces significant execution risks as it develops solid-state battery technology. Analyst sentiment is cautious with 73% hold ratings, though the consensus price target of $10.35 suggests potential upside if commercialization milestones are met.
QS represents a high-risk, high-reward opportunity in the pre-revenue EV battery space. The primary investment thesis hinges on successful commercialization of solid-state batteries by 2029, but competition and execution delays pose substantial risks. Current negative ROE of -39.08% and cash burn require careful monitoring of funding runway and partnership developments with automotive manufacturers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
